John M Vierling1, Stefan Zeuzem2, Fred Poordad3, Jean-Pierre Bronowicki4, Michael P Manns5, Bruce R Bacon6, Rafael Esteban7, Steven L Flamm8, Paul Y Kwo9, Lisa D Pedicone10, Weiping Deng10, Frank J Dutko10, Mark J DiNubile10, Kenneth J Koury10, Frans A Helmond10, Janice Wahl10, Savino Bruno11. 1. Baylor College of Medicine, Houston, TX, USA. Electronic address: vierling@bcm.edu. 2. JW Goethe University Hospital, Frankfurt, Germany. 3. University of Texas Health Science Center, San Antonio, TX, USA. 4. INSERMU954, CHU de Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France. 5. Medical School of Hannover, Hannover, Germany. 6. Saint Louis University School of Medicine, St. Louis, MO, USA. 7. Vall d'Hebron University Hospital, Barcelona, Spain. 8. Northwestern Feinberg School of Medicine, Chicago, IL, USA. 9. Indiana University School of Medicine, Indianapolis, IN, USA. 10. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA. 11. A.O. Fatebenefratelli e Oftalmico, Milan, Italy.
Abstract
BACKGROUND & AIMS: HCV-infected cirrhotics may urgently need therapy but are often under-represented in clinical trials resulting in limited data to guide their management. We performed a meta-analysis of well-compensated cirrhotic patients from five Phase 3 trials. METHODS: Patients received P/R (peginterferon/ribavirin; 4 weeks) followed by BOC (boceprevir)/P/R or P/R for 24, 32, or 44 weeks. Sustained virologic response (SVR) rates were calculated by Metavir score. Multivariate logistic regression (MLR) models identified baseline and on-treatment predictors of SVR. Safety was evaluated by adverse-event (AE) reporting and laboratory monitoring. RESULTS: Pooled meta-estimates for SVR rates (95% confidence interval) in 212 F4 (cirrhotic) patients were 55% (43, 66) with BOC/P/R vs.17% (0, 41) with P/R. MLR identified 4 predictors of SVR in F3/F4 patients: undetectable HCV-RNA at treatment week (TW) 8; ⩾ 1 log10 decline in HCV-RNA from baseline at TW4; male; and baseline HCV-RNA ⩽ 800,000 IU/ml. SVR rate was 89% (65/73) in F4 patients who were HCV-RNA undetectable at TW8. No F3 (0/5) or F4 (0/17) patients with <3 log10 decline and detectable HCV-RNA at TW8 achieved SVR. Anemia and diarrhea occurred more frequently in cirrhotic than non-cirrhotic patients. Serious AEs, discontinuations due to an AE, interventions to manage anemia, infections, and thrombocytopenia occurred more frequently in cirrhotics with BOC/P/R than P/R. Potential hepatic decompensation and/or sepsis were identified in 2 P/R and 3 BOC/P/R recipients. CONCLUSIONS: BOC/P/R appears to have a generally favorable benefit-risk profile in compensated cirrhotic patients. SVR rates were particularly high in cirrhotic patients with undetectable HCV-RNA at TW8.
BACKGROUND & AIMS: HCV-infected cirrhotics may urgently need therapy but are often under-represented in clinical trials resulting in limited data to guide their management. We performed a meta-analysis of well-compensated cirrhotic patients from five Phase 3 trials. METHODS:Patients received P/R (peginterferon/ribavirin; 4 weeks) followed by BOC (boceprevir)/P/R or P/R for 24, 32, or 44 weeks. Sustained virologic response (SVR) rates were calculated by Metavir score. Multivariate logistic regression (MLR) models identified baseline and on-treatment predictors of SVR. Safety was evaluated by adverse-event (AE) reporting and laboratory monitoring. RESULTS: Pooled meta-estimates for SVR rates (95% confidence interval) in 212 F4 (cirrhotic) patients were 55% (43, 66) with BOC/P/R vs.17% (0, 41) with P/R. MLR identified 4 predictors of SVR in F3/F4 patients: undetectable HCV-RNA at treatment week (TW) 8; ⩾ 1 log10 decline in HCV-RNA from baseline at TW4; male; and baseline HCV-RNA ⩽ 800,000 IU/ml. SVR rate was 89% (65/73) in F4 patients who were HCV-RNA undetectable at TW8. No F3 (0/5) or F4 (0/17) patients with <3 log10 decline and detectable HCV-RNA at TW8 achieved SVR. Anemia and diarrhea occurred more frequently in cirrhotic than non-cirrhotic patients. Serious AEs, discontinuations due to an AE, interventions to manage anemia, infections, and thrombocytopenia occurred more frequently in cirrhotics with BOC/P/R than P/R. Potential hepatic decompensation and/or sepsis were identified in 2 P/R and 3 BOC/P/R recipients. CONCLUSIONS: BOC/P/R appears to have a generally favorable benefit-risk profile in compensated cirrhotic patients. SVR rates were particularly high in cirrhotic patients with undetectable HCV-RNA at TW8.
Authors: Karin Neukam; Daniela I Munteanu; Antonio Rivero-Juárez; Thomas Lutz; Jan Fehr; Mattias Mandorfer; Sanjay Bhagani; Luis F López-Cortés; Annette Haberl; Marcel Stoeckle; Manuel Márquez; Stefan Scholten; Ignacio de Los Santos-Gil; Stefan Mauss; Antonio Rivero; Antonio Collado; Marcial Delgado; Juergen K Rockstroh; Juan A Pineda Journal: PLoS One Date: 2015-04-29 Impact factor: 3.240
Authors: Helena H Borba; Astrid Wiens; Laiza M Steimbach; Cassio M Perlin; Fernanda S Tonin; Maria L A Pedroso; Fernando Fernandez-Llimos; Roberto Pontarolo Journal: Eur J Clin Pharmacol Date: 2016-10-19 Impact factor: 3.064
Authors: Nancy Reau; Michael W Fried; David R Nelson; Robert S Brown; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Joseph K Lim; Paul J Pockros; K Rajender Reddy; Kenneth E Sherman Journal: Liver Int Date: 2015-11-22 Impact factor: 5.828